Skip to main content
Back
Watch Compare

Protagenic Therapeutics, Inc.\new

Data quality: 100%
Also listed as PTIXW OTC
PTIX
OTC Manufacturing Chemicals
$0.59
▼ $0.11 (-15.22%)
Mkt Cap: 1.34 M
Price
$0.69
Mkt Cap
1.34 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -3.30 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio0.34
Interest Coverage-28.83

Valuation

PE (TTM)
-0.27
Above sector avg (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -0.3 -1.5
P/B — 1.6
ROE % — -54.0
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

No analyst coverage available

Earnings Estimates

No forward estimates available

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -4.99 M
ROE N/A ROA -105.70%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3.30 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.34
Interest Coverage -28.83 Asset Turnover 0.00
Working Capital -4.52 M Tangible Book Value -4.49 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.27 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -247.25%
Market Cap 1.34 M Enterprise Value 1.34 M
Per Share
EPS (Diluted TTM) -4.10 Revenue / Share 0.00
FCF / Share -1.71 OCF / Share -1.71
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 66.21%
SBC-Adj. FCF -3.86 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 0.0 0.0 0.0 0.0 —
Net Income -5.53 M -5.00 M -3.56 M -4.52 M -2.55 M
EPS (Diluted) -1.13 -1.15 — — —
Gross Profit — — — — —
Operating Income -5.70 M -4.53 M -3.56 M -4.14 M -2.55 M
EBITDA — — — — —
R&D Expenses 3.84 M 3.32 M 1.59 M 1.14 M 699,797.0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 107,682.0 107,682.0 137,456.0 496,912.0 —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 1.96 M 4.32 M 8.04 M 11.06 M 879,247.0
Total Liabilities 942,759.0 655,252.0 1.12 M 1.12 M 2.03 M
Shareholders' Equity 1.01 M 3.67 M 6.92 M 9.94 M -1.15 M
Total Debt — — — — —
Cash & Equivalents — — — — 671,091.0
Current Assets 1.88 M 4.20 M 8.04 M 11.06 M 879,247.0
Current Liabilities 942,759.0 655,252.0 1.12 M 799,535.0 655,187.0